ACCESS Newswire

iZafe Group

Share
Dosell Consumer Ready for Broad Launch after Successful Pilot Project

STOCKHOLM, SE / ACCESSWIRE / September 07, 2021 / iZafe Group (STO:IZAFE-B)

iZafe Group AB (publ.) announces that their pilot project with consumers now has been completed with a positive result, which paves the way for a successful launch in the Swedish and Italian markets. The test participators in the pilot project have had their say: Dosell Consumer is an appreciated aid on the market.

During the summer, a pilot project was carried out with twenty people from a group of several hundred interested who tested Dosell Consumer on their own behalf or to help a relative. Participants have continuously evaluated the product and given suggestions for improvements that iZafe Group is working to update ahead of the upcoming launch of Dosell Consumer.

After the test period, iZafe Group has made a final evaluation with the participants to identify how their medication has developed since they started using Dosell and to get information about their attitude to continue with the service .

"Dosell is my best friend - I never want to be without it." "The robot has reduced my medication misses on the weekends when you have a lot of other things scheduled." "I have received better continuous medication at fixed times. "Dosell increased the security of my mother and reduced my anxiety - Dosell can definitely extend the period of independence." "I would not be able to function without my Dosell." "My daughter does not want to be without Dosell and go back to manual handling of medication where I am constantly unsure and have to remind several times a day that medication should be taken." Dosell is missed by both the home care service and by my mother. It made it very easy to remember to take the medicine on time. It was calming to know that the medicine was delivered. " The words from users or relatives who participated as test persons in the pilot project during the summer of 2021 show that Dosell Consumer is an appreciated aid on the market that you do not want to be without.

"The interest in testing Dosell Consumer has been great and I can state that the response has been very good. The twenty people who participated in the test period have been completely different profiles, which indicates that Dosell is suitable for a number of different customer groups. As many as 95 percent want to keep their Dosell and continue with the service. They appreciate that Dosell is easy to use and that their compliance has improved. This strengthens us ahead of the upcoming launch to the public", says Anders Segerström, CEO of iZafe Group.

The enthusiastic response and the positive reception of the consumer version in Sweden means that iZafe Group is ready to start the launch in Italy via the Sempli Farma service, where the concept of sachets has been developed and spread more widely. The Italian market has a considerable potential with the equivalent of 8.8 million inhabitants over the age of 65 consuming more than five different medications per day. Of these, more than 50 percent experience difficulty following their medication treatments. In Italy, there is an accelerating need to automate medication management, where the consumer version of Dosell has been requested as the obvious alternative.

"The Italian market is several times as large as the Swedish and we see incredible potential for a broad rollout of Dosell now that Italy begins its digitalization journey in healthcare to give more people a safer and simpler medication at home, something that according to society's ambition contributes to lower healthcare costs with reduced risk of incorrect medication. The Italian sachets have been validated with Dosell and active marketing is done towards pharmacies." concludes Anders Segerström.

Following the launch of Dosell Consumer in Sweden and Italy, iZafe Group sees great potential in a number of other markets in Europe, such as Norway, Finland, Spain, Portugal and England, where the company plans to find the right partners to launch the consumer version in longer term.

About Dosell Consumer
Dosell Consumer and the Dosell app are a niche version of iZafe Group's professional solution and adapted so that users and relatives can administer medication and ensure the right dosage themselves, without being dependent on healthcare professionals. Both versions of the product are compatible with sachets from all suppliers on the market.

Dosell Consumer is a subscription service. Subscriptions for Dosell Consumer can be subscribed for and paid for by, for example, relatives on behalf of the user.

Dosell Consumer will be available for delivery in October 2021, but it is already possible to register an interest for when Dosell Consumer is launched.

About Sempli Farma by Remedio
The Italian healthcare company Remedio has built a network of strategically selected partners in Italy to identify a combination of different aids to medication management and distribution channels that enable the elderly to remain at home longer. Unlike in Sweden, the possibility of receiving medicine separated into daily doses has not existed previously in Italy; this has inspired Remedio to launch the concept of sachets and develop a complete solution called Sempli Farma.

Sempli Farma is a service that, via pharmacies, connects doctors with the patient and their relatives through a closed drug-dispensing system. The aim of the care concept is to reduce care costs and streamline the Italian healthcare system. Dosell will become the ultimate end component by delivering the sachets while confirming that the medication has been taken and recording statistics.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se . Further information is available at www.izafe.se/investor-relations/ .

Attachments

Dosell Consumer ready for broad launch after successful pilot project

SOURCE: iZafe Group



View source version on accesswire.com:
https://www.accesswire.com/662947/Dosell-Consumer-Ready-for-Broad-Launch-after-Successful-Pilot-Project

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Jama Connect(R) Attains Level 2 TISAX Certification from TÜV SÜD9.7.2025 13:00:00 CEST | Press release

Jama Connect is the only requirements management application that is both TISAX and SOC 2 certified PORTLAND, OR / ACCESS Newswire / July 9, 2025 / Jama Software®, the industry leading requirements management and traceability solution provider, announced today that it has achieved Level 2 Trusted Information Security Assessment Exchange (TISAX) certification from TÜV SÜD. TISAX is a security standard created by the German Association of the Automotive Industry (VDA). Jama Connect® is now the only requirements management application that is both TISAX and SOC 2 certified. This achievement underscores Jama Software's unwavering commitment to information security and data protection. TISAX certification is a critical benchmark for meeting the stringent security requirements of German OEMs and their global supply chains, ensuring that sensitive customer and product data is handled with the highest standards of confidentiality, integrity, and availability. For our customers, this certificat

AGFA HealthCare Achieves HITRUST I1 Certification, Demonstrating Its Commitment to and Compliance With Data Protection Standards, and Protecting Against Cybersecurity Threats9.7.2025 10:00:00 CEST | Press release

HITRUST certification validates that AGFA HealthCare is operating using leading security practices to protect sensitive information. MORTSEL, BE / ACCESS Newswire / July 9, 2025 / AGFA HealthCare, a leading provider of Imaging IT, today announced that its Enterprise Imaging Solutions earned certified status by HITRUST for information security.AGFA HealthCare HITRUST i1 certification demonstrates that AGFA HealthCare's Enterprise Imaging Solutions are leveraging a comprehensive standard, covering 182 control requirements - including mappings to over 40 authoritative sources - to protect against current and emerging threats. The HITRUST i1 Validated Assessment and Certification allows organizations to demonstrate that they address cybersecurity challenges and remain cyber resilient over time. "HITRUST i1 Certification gives our internal and external stakeholders confidence that we are following leading security practices," said Nathalie McCaughley, President at AGFA HealthCare. Jarius Ja

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models8.7.2025 14:30:00 CEST | Press release

Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champions Oncology (NASDAQ:CSBR) a leading translational oncology research organization, today announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft (PDX) tumor models, enabling drug developers to evaluate radiolabeled agents in clinically r

Karbon-X Becomes Official Name Sponsor of BK Dukes Basketball Team8.7.2025 09:00:00 CEST | Press release

CALGARY, AB / ACCESS Newswire / July 8, 2025 / Karbon-X Corp. (OTCQX:KARX), a vertically integrated climate solutions company, has signed a multi-year agreement to become the official name sponsor of BK Dukes, one of Austria's top professional basketball teams. Effective immediately, the team will compete as the BK Karbon-X Dukes. This partnership brings together two high-performance organizations committed to community, innovation, and progress chon and off the court. Fresh off their 2024-2025 Austrian Cup Title win, the BK Dukes are working with Karbon-X to integrate measurable sustainability initiatives throughout the organization. This includes annual emissions reporting, offsetting all team and venue Scope 1, 2, and 3 emissions, and incorporating an emissions offset fee into every ticket purchase to address fan-related impacts. Together, they are building a model of leadership that extends far beyond the scoreboard. "This partnership represents what climate action should look like

Polaris Renewable Energy Announces Q1 2025 Investor Call Details7.7.2025 22:10:00 CEST | Press release

TORONTO, ON / ACCESS Newswire / July 7, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q2 2025 Earnings Results on Thursday, July 31st, 2025, at 10:00 am EST. To listen to the call, please dial Toll Free 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 108489. or URL: https://www.webcaster4.com/Webcast/Page/2773/51833 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51833 International (toll-free): 1 919-882-2331, Passcode: 51833 Encore Replay Expiration Date: August 14, 2025 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye